Literature DB >> 15196261

Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome.

K Mizuno1, A Yachie, S Nagaoki, H Wada, K Okada, M Kawachi, T Toma, A Konno, K Ohta, Y Kasahara, S Koizumi.   

Abstract

Although triggering by infectious agents and abnormal immune responses may play some role in the pathogenesis of juvenile dermatomyositis syndrome (JDMS), the precise mechanism of muscle destruction and vascular damage is largely unknown. In this study, we tried to elucidate the role of cytotoxic T cells in two patients with JDMS, who were diagnosed based on the characteristic symptoms, laboratory data, MRI findings and electromyographic patterns. Peripheral blood T cell phenotypes were determined by flow cytometry, using mAbs against specific T cell receptor (TCR) Vbetas. Complementarity-determining region3 (CDR3) size analysis was performed by gene scanning of CDR3 polymerase chain reaction (PCR) amplification products specific for each Vbeta. Subsequently, CDR3 nucleotide sequences were obtained after cloning of the predominant products. The distribution of lymphocytes infiltrating the muscle tissue was analysed by immunohistochemistry. In both patients examined, a unique combination of TCR Vbeta repertoires was increased within the CD8+ T cells. These subpopulations expressed a characteristic phenotype, indicating that they are memory/effector T cells with killer functions. At the same time, immunohistological and molecular biological examinations of the biopsied muscle samples revealed that identical CD8+ T cell clones with identical phenotypes/TCR Vbeta infiltrated within the inflammatory tissue, in particular around vessels. These findings indicate that oligoclonal expansion of CD8+ T cells plays a central role in the pathogenesis of muscle injury in the juvenile form of dermatomyositis syndrome and may provide a useful clinical parameter of disease activity and responsiveness to anti-inflammatory therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196261      PMCID: PMC1809070          DOI: 10.1111/j.1365-2249.2004.02500.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Diversity of human alpha beta T cell receptors.

Authors:  T P Arstila; A Casrouge; V Baron; J Even; J Kanellopoulos; P Kourilsky
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

2.  Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis.

Authors:  Mineki Saito; Itsuro Higuchi; Akiko Saito; Shuji Izumo; Koichiro Usuku; Charles R M Bangham; Mitsuhiro Osame
Journal:  J Infect Dis       Date:  2002-10-07       Impact factor: 5.226

3.  Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population.

Authors:  M P Weekes; M R Wills; K Mynard; R Hicks; J G Sissons; A J Carmichael
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

4.  Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis.

Authors:  J Nishio; M Suzuki; N Miyasaka; H Kohsaka
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

5.  Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis.

Authors:  Margherita Massa; Nick Costouros; Federica Mazzoli; Fabrizio De Benedetti; Antonio La Cava; Tho Le; Isme De Kleer; Angelo Ravelli; Margaret Liotta; Sarah Roord; Charles Berry; Lauren M Pachman; Alberto Martini; Salvatore Albani
Journal:  Arthritis Rheum       Date:  2002-11

6.  Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients.

Authors:  O Benveniste; P Chérin; T Maisonobe; R Merat; O Chosidow; L Mouthon; L Guillevin; A Flahault; M C Burland; D Klatzmann; S Herson; O Boyer
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

7.  Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis.

Authors:  M R O'Gorman; L Bianchi; D Zaas; V Corrochano; L M Pachman
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

8.  Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis.

Authors:  Zivana Tezak; Eric P Hoffman; Jennica L Lutz; Tamara O Fedczyna; Dietrich Stephan; Eric G Bremer; Irina Krasnoselska-Riz; Ajit Kumar; Lauren M Pachman
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

9.  Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells.

Authors:  Y Kikuchi; S Koarada; Y Tada; O Ushiyama; F Morito; N Suzuki; A Ohta; T Horiuchi; K Miyake; K Nagasawa
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

10.  Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence.

Authors:  Hartwig W Lehmann; Lucia Kühner; Karin Beckenlehner; Esther Müller-Godeffroy; Karl-Günter Heide; Rolf-Michael Küster; Susanne Modrow
Journal:  J Clin Virol       Date:  2002-08       Impact factor: 3.168

View more
  10 in total

Review 1.  Recent advances in juvenile dermatomyositis.

Authors:  Ann M Reed; Thomas Mason
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

2.  Analysis of T cell receptor Vbeta diversity in peripheral CD4 and CD8 T lymphocytes in patients with autoimmune thyroid diseases.

Authors:  M Okajima; T Wada; M Nishida; T Yokoyama; Y Nakayama; Y Hashida; F Shibata; Y Tone; A Ishizaki; M Shimizu; T Saito; K Ohta; T Toma; A Yachie
Journal:  Clin Exp Immunol       Date:  2008-11-25       Impact factor: 4.330

Review 3.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

4.  Clonotypic analysis of T cell reconstitution after haematopoietic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency.

Authors:  H Okamoto; C Arii; F Shibata; T Toma; T Wada; M Inoue; Y Tone; Y Kasahara; S Koizumi; Y Kamachi; Y Ishida; J Inagaki; M Kato; T Morio; A Yachie
Journal:  Clin Exp Immunol       Date:  2007-03-21       Impact factor: 4.330

5.  Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome.

Authors:  Taizo Wada; Shepherd H Schurman; Elizabeth K Garabedian; Akihiro Yachie; Fabio Candotti
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

6.  MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement.

Authors:  Kevin A O'Connor; Kathy A Abbott; Brad Sabin; Maxine Kuroda; Lauren M Pachman
Journal:  Clin Immunol       Date:  2006-07-21       Impact factor: 3.969

7.  Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis.

Authors:  T Fujiyama; T Ito; N Ogawa; T Suda; Y Tokura; H Hashizume
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 8.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

9.  Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease.

Authors:  Yongdong Zhao; Tamara O Fedczyna; Violet McVicker; Jan Caliendo; Honglin Li; Lauren M Pachman
Journal:  Clin Immunol       Date:  2007-08-20       Impact factor: 3.969

10.  Oligoclonal expansions of CD4+ and CD8+ T-cells in the target organ of patients with biliary atresia.

Authors:  Cara L Mack; Michael T Falta; Andrew K Sullivan; Frederick Karrer; Ronald J Sokol; Brian M Freed; Andrew P Fontenot
Journal:  Gastroenterology       Date:  2007-04-20       Impact factor: 22.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.